| Marissa Grotzke, MD | |
|
615 Arapeen Dr, Suite 100, Salt Lake City, UT 84108-1267 | |
| (801) 587-3969 | |
| (801) 587-3997 |
| Full Name | Marissa Grotzke |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Endocrinology, Diabetes & Metabolism |
| Location | 615 Arapeen Dr, Salt Lake City, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245425032 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 5525882-1205 (Utah) | Primary |
| Entity Name | University Of Utah Adult Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114321981 PECOS PAC ID: 0941525273 Enrollment ID: O20150209001683 |
News Archive
A group of researchers at the Institute for Research in Immunology and Cancer (IRIC) of Université de Montréal discovered a promising new approach to treating leukemia by disarming a gene that is responsible for tumor progression.
Bruin Biometrics, LLC has been granted U.S. Food and Drug Administration marketing authorization for the SEM Scanner, becoming the world's first FDA-authorised device to objectively alert clinicians to specific anatomical areas of a patient's body at increased risk for developing pressure damage.
Tolero Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company developing treatments for oncology and blood disorders, reported positive interim results from an ongoing, randomized Phase 2 clinical trial of its lead drug candidate, alvocidib, in combination with cytarabine plus mitoxantrone for previously untreated acute myeloid leukemia (AML) patients.
"More than 100 public health experts have wrapped up a three-day meeting in Geneva to review a Global Action Plan for Influenza Vaccines that was developed in 2006, and to develop a strategic plan of action for the next five years," VOA News reports, noting that the WHO "says the world is better prepared for the next influenza pandemic than it was in the past".
Cystoid macular edema (CME) is a common complication of retinitis pigmentosa (RP), a family of retinal diseases in which patients typically lose night and side vision first and then develop impaired central vision. CME can also decrease central vision.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marissa Grotzke, MD 615 Arapeen Dr, Suite 100, Salt Lake City, UT 84108-1267 Ph: (801) 587-3969 | Marissa Grotzke, MD 615 Arapeen Dr, Suite 100, Salt Lake City, UT 84108-1267 Ph: (801) 587-3969 |
News Archive
A group of researchers at the Institute for Research in Immunology and Cancer (IRIC) of Université de Montréal discovered a promising new approach to treating leukemia by disarming a gene that is responsible for tumor progression.
Bruin Biometrics, LLC has been granted U.S. Food and Drug Administration marketing authorization for the SEM Scanner, becoming the world's first FDA-authorised device to objectively alert clinicians to specific anatomical areas of a patient's body at increased risk for developing pressure damage.
Tolero Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company developing treatments for oncology and blood disorders, reported positive interim results from an ongoing, randomized Phase 2 clinical trial of its lead drug candidate, alvocidib, in combination with cytarabine plus mitoxantrone for previously untreated acute myeloid leukemia (AML) patients.
"More than 100 public health experts have wrapped up a three-day meeting in Geneva to review a Global Action Plan for Influenza Vaccines that was developed in 2006, and to develop a strategic plan of action for the next five years," VOA News reports, noting that the WHO "says the world is better prepared for the next influenza pandemic than it was in the past".
Cystoid macular edema (CME) is a common complication of retinitis pigmentosa (RP), a family of retinal diseases in which patients typically lose night and side vision first and then develop impaired central vision. CME can also decrease central vision.
› Verified 6 days ago
Dr. Mehmet Akkaya, M.D Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: University Of Utah Hospital Cardiology, 3o N,1900 E, Rm:4a100, Salt Lake City, UT 84132 Phone: 801-505-1689 | |
Dr. Willard Dere, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 500 Foothill Blvd, Salt Lake City, UT 84148 Phone: 801-582-1565 | |
Megan Meier, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 50 N Medical Dr, Salt Lake City, UT 84132 Phone: 801-581-2121 | |
Joel Money, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 50 N Medical Dr, Salt Lake City, UT 84132 Phone: 801-581-2121 | |
Mchale O. Anderson, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 30 N 1900 E Rm 4a100, Salt Lake City, UT 84132 Phone: 801-587-2451 | |
Siddharth K. Iyengar, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 30 N 1900 E Rm 4c116, Salt Lake City, UT 84132 Phone: 801-581-7606 | |
Taryn A. Young, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 5121 S Cottonwood St, Salt Lake City, UT 84107 Phone: 801-507-4384 Fax: 801-507-4398 |